Biophytis Reports Positive Half-Year 2026 Financial Results and Strategic Advances

Biophytis SA announced its financial results for the first half of 2026, highlighting progress in its clinical programs. The company achieved a 38% reduction in net loss, amounting to €2.7 million. This improvement stems from a notable decrease in both research and administrative expenses. Operating loss was reduced by 39% to €2.9 million.

Biophytis has expanded its strategic partnerships, particularly in Asia. A joint venture was established in Hong Kong to support the commercialization of BIO101, targeting sarcopenia. The venture holds a commitment for up to $20 million funding over three years.

For obesity treatments, Biophytis is set to launch the OBA study of BIO101 combined with GLP-1 in various regions, fully funded through recent capital increases and partnerships. The study aims to assess muscle preservation amidst weight loss.